Emma Pollard

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Alphapharm has been developing and making generic medicines in Australia for more than 25 years. Millions of Australians take an Alphapharm generic medicine every day. In fact, It has become the largest supplier of medicines to the government subsidised Pharmaceutical Benefits Scheme and Australia's leader in generic medicines. Alphapharm medicines are available Australia-wide. Alphapharm medicines are made to the highest global quality standards and exported to more than 50 countries, including those in Europe and the US. Globally, Alphapharm is part of Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third-largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.